Enfusion, Inc. (NYSE:ENFN) Short Interest Up 19.1% in August

Enfusion, Inc. (NYSE:ENFN) was the recipient of a large increase in short interest during the month of August. As of August 15th, there was short interest totalling 2,310,000 shares, an increase of 19.1% from the July 31st total of 1,940,000 shares. Approximately 4.7% of the company’s shares are sold short. Based on an average daily volume of 376,800 shares, the days-to-cover ratio is presently 6.1 days.

Insiders Place Their Bets

In other news, insider Bronwen Bastone sold 18,241 shares of the company’s stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $8.11, for a total value of $147,934.51. Following the sale, the insider now directly owns 198,913 shares of the company’s stock, valued at approximately $1,613,184.43. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, insider Bronwen Bastone sold 18,241 shares of Enfusion stock in a transaction dated Thursday, June 20th. The stock was sold at an average price of $8.11, for a total value of $147,934.51. Following the completion of the transaction, the insider now directly owns 198,913 shares of the company’s stock, valued at approximately $1,613,184.43. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Deirdre Somers sold 4,629 shares of the business’s stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $8.40, for a total value of $38,883.60. Following the completion of the transaction, the director now directly owns 43,312 shares in the company, valued at $363,820.80. The disclosure for this sale can be found here. In the last 90 days, insiders sold 36,318 shares of company stock worth $296,688. 36.44% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Enfusion

Hedge funds have recently modified their holdings of the company. Allspring Global Investments Holdings LLC purchased a new stake in shares of Enfusion during the first quarter valued at approximately $44,000. RiverPark Advisors LLC bought a new stake in shares of Enfusion during the 2nd quarter worth $68,000. Arizona State Retirement System purchased a new position in shares of Enfusion in the 2nd quarter worth about $86,000. Price T Rowe Associates Inc. MD bought a new position in Enfusion during the first quarter valued at about $102,000. Finally, Quadrature Capital Ltd purchased a new stake in Enfusion during the first quarter worth about $109,000. Institutional investors own 81.05% of the company’s stock.

Enfusion Trading Up 1.1 %

NYSE ENFN opened at $8.29 on Monday. The business has a fifty day simple moving average of $8.60 and a 200 day simple moving average of $8.95. Enfusion has a 12 month low of $7.52 and a 12 month high of $10.45. The firm has a market capitalization of $1.06 billion, a P/E ratio of 276.33, a PEG ratio of 2.30 and a beta of 0.92.

Enfusion (NYSE:ENFN) last announced its earnings results on Tuesday, August 6th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). Enfusion had a net margin of 1.98% and a return on equity of 6.17%. The firm had revenue of $49.46 million during the quarter, compared to analysts’ expectations of $50.27 million. As a group, sell-side analysts predict that Enfusion will post 0.07 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Morgan Stanley began coverage on shares of Enfusion in a research report on Friday, May 10th. They issued an “overweight” rating and a $11.00 price target for the company. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, Enfusion has an average rating of “Hold” and a consensus price target of $9.33.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.